ZBIO

Zenas Biopharma Inc

31.27

Aug 28 • 3:59 PM ET -1.35 (-4.14%)

30.76

Aftermarket • 7:43 PM ET -0.51 (-1.63%)

Healthcare Biotechnology USA Mid NASD

Peers: RYTM KYMR VKTX BMRN CRNX INCY KRYS AXSM MDGL NBIX

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO IWC FFSM

Scroll to Statements

Index	RUT
Market Cap	2.04B
Enterprise Value	1.78B
Income	-484.38M
Sales	1.00M
Book/sh	3.90
Cash/sh	9.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	167
IPO	Sep 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	2038.08
P/B	8.01
P/C	3.17
P/FCF	-
EV/EBITDA	-
EV/Sales	1784.55
Quick Ratio	9.93
Current Ratio	9.93
Debt/Eq	1.58
LT Debt/Eq	1.57
Option/Short	Yes / Yes

EPS (ttm)	-9.61
EPS next Y	-4.95
EPS next Q	-1.22
EPS this Y	34.21%
EPS next Y	10.88%
EPS next 5Y	22.18%
EPS past 3/5Y	-39.47% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-127.13%
Sales Y/Y TTM	-93.33%
EPS Q/Q	-41.57%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-57.71% -93.33%

Insider Own	47.63%
Insider Trans	1.31%
Inst Own	67.18%
Inst Trans	11.94%
ROA	-97.39%
ROE	-199.04%
ROIC	-76.18%
Gross Margin	96.90%
Oper. Margin	-27390.10%
Profit Margin	-48438.40%
SMA20	-1.26%
SMA50	6.12%
SMA200	19.98%
Trades

Shs Outstand	63.33M
Shs Float	34.13M
Short Float	34.16%
Short Ratio	13.72
Short Interest	11.66M
52W High	44.60 -29.89%
52W Low	13.50 131.63%
Volatility	5.21% 6.00%
ATR (14)	1.86
RSI (14)	50.84
Beta	-1.02
Rel Volume	0.52
Avg Volume	849.73K
Volume	439,141

Perf Week	-3.16%
Perf Month	-3.10%
Perf Quarter	69.95%
Perf Half Y	18.67%
Perf YTD	-13.88%
Perf Year	92.31%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.25
Target Price	47.00
Prev Close	32.62
Price	31.27
Change %	-4.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Aug-28-26 07:46PM	Fortune Brands and 4 More Stocks See Action From Activist Investors (Barrons.com)
Aug-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-26 07:00AM	Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -6.68%
Jul-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.46%
04:15PM	Loading…
Jun-11-26 04:15PM	Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire) +11.49%
Jun-02-26 07:05PM	Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine (GlobeNewswire) -5.72%
May-28-26 07:05AM	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD (GlobeNewswire)
May-19-26 07:05AM	Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress (GlobeNewswire) +5.50%
May-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.80%
May-13-26 06:50AM	Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor (GlobeNewswire)
06:00AM	Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-26 12:12AM	Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million (GlobeNewswire) -17.82%
Mar-26-26 04:01PM	Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock (GlobeNewswire)
06:01PM	Loading…
Mar-16-26 06:01PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-26 10:56AM	Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory (Insider Monkey)
Feb-20-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-26 07:09AM	Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4 (Insider Monkey)
Feb-16-26 04:07AM	Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit (MarketBeat)
Feb-09-26 07:05AM	Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 (GlobeNewswire)
Feb-04-26 07:05AM	Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-26 09:01AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Jan-07-26 06:46AM	Zenas BioPharma Touts Phase 3 Win, But Stock Crashes (Benzinga) +8.62%
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks) -8.49%
06:25AM	Zenas stock drops 51% despite lead assets Phase III rare disease win (Clinical Trials Arena)
Jan-05-26 04:23PM	Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. (Investor's Business Daily) -51.86%
07:05AM	Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
06:26AM	Loading…
06:26AM	Zenas shares crash after top drug misses expectations in immune disease study (BioPharma Dive)
Dec-19-25 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +17.10%
Dec-15-25 07:05AM	Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus (GlobeNewswire) -19.71%
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-03-25 07:25AM	Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation (Insider Monkey) +6.29%
Nov-12-25 07:05AM	Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) +8.41%
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat) -5.06%
08:35AM	Zenas bifunctional mAb scores at Phase II in relapsing MS (Clinical Trials Arena)
06:00AM	Incyte trims pipeline; Zenas surges on MS drug results (BioPharma Dive)
Oct-27-25 07:05AM	Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis (GlobeNewswire) +33.08%
Oct-08-25 05:00AM	Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) +24.22%
Sep-02-25 07:05AM	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million (GlobeNewswire) +9.50%
Aug-26-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-12-25 07:05AM	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.68%
Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

M.B.A.Mr. Leon Oliver Moulder Jr.

COO & PresidentMr. Joseph L. Farmer

Head of Research & Development and Chief Medical OfficerDr. Lisa von Moltke M.D.

Chief Business Officer & CFOMs. Jennifer A. Fox

Chief Technical OfficerDr. Heinrich Schlieker Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zebra Aggregator, LP	Affiliate	Aug 19 '26	Proposed Sale	31.91	1,000,000	31,910,000		Aug 19 04:15 PM
MOULDER LEON O JR	Chief Executive Officer	May 18 '26	Buy	16.88	60,000	1,012,800	96,928	May 18 09:12 PM
MOULDER LEON O JR	Chief Executive Officer	Apr 29 '26	Buy	17.62	35,000	616,700	1,786,039	Apr 29 07:21 PM
MOULDER LEON O JR	Chief Executive Officer	Apr 28 '26	Buy	18.02	25,000	450,500	1,751,039	Apr 29 07:21 PM
Lu Hongbo	Director	Mar 31 '26	Buy	18.63	3,768	70,198	426,736	Apr 02 05:02 PM
Fairmount Funds Management LLC	Director	Mar 31 '26	Buy	20.00	150,000	3,000,000	2,359,025	Apr 01 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Mar 31 '26	Buy	19.31	34,000	656,540	1,726,039	Mar 31 08:14 PM
MOULDER LEON O JR	Chief Executive Officer	Mar 30 '26	Buy	18.23	20,000	364,600	1,692,039	Mar 31 08:14 PM
Lu Hongbo	Director	Mar 31 '26	Buy	20.00	75,000	1,500,000	422,968	Mar 31 05:00 PM
Lu Hongbo	Director	Feb 11 '26	Buy	22.50	25,985	584,662	347,968	Feb 13 05:35 PM
Allen Patricia L	Director	Feb 12 '26	Buy	24.85	15,700	390,088	15,700	Feb 13 05:06 PM
Allen Patricia L	Director	Feb 13 '26	Buy	26.36	4,160	109,658	19,860	Feb 13 05:06 PM
MOULDER LEON O JR	Chief Executive Officer	Feb 02 '26	Buy	17.96	57,000	1,023,720	423,155	Feb 03 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 07 '26	Buy	16.38	50,000	819,000	316,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 08 '26	Buy	16.30	30,000	489,000	346,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 09 '26	Buy	16.55	20,000	331,000	366,155	Jan 09 09:42 PM
Nunn Jason Raleigh	Director	Oct 09 '25	Buy	19.00	63,158	1,200,002	1,173,395	Oct 14 05:16 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Oct 09 '25	Buy	19.00	126,315	2,399,985	1,917,895	Oct 14 05:14 PM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	19.00	105,265	2,000,035	1,832,669	Oct 14 08:59 AM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	20.85	11,990	249,992	11,990	Oct 14 08:59 AM
MOULDER LEON O JR	See Remarks	Oct 07 '25	Buy	20.85	36,928	769,949	36,928	Oct 09 05:24 PM
Fairmount Funds Management LLC	Director	Oct 07 '25	Buy	19.00	316,219	6,008,161	2,209,025	Oct 09 04:15 PM
Lu Hongbo	Director	Oct 07 '25	Buy	19.00	263,160	5,000,040	321,983	Oct 09 03:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZBIO

Zenas Biopharma Inc

Upgrade your Finviz experience